HSBC's analysts have expressed a lack of confidence in AstraZeneca's ability to maintain its historical valuation, primarily due to a recent failure in a late-stage clinical trial for a heart disease drug. This failure led to a significant drop in AstraZeneca's shares, which fell as much as 9% on the day of the announcement.
The bank has revised its target price for the stock down to £137.50 ($183.95) from £165, reflecting a more than 16% decrease. Analysts noted that the company's strong historical performance has been largely driven by investor confidence in its research and development capabilities.
However, with the recent trial failure and potential for further negative outcomes, there are concerns that AstraZeneca may face a loss of confidence in its R&D engine, which could lead to a reevaluation of its market position.
Over the past 14 years under CEO Pascal Soriot, AstraZeneca has built a reputation for successful drug development, but the recent downturn in share price, now down 12% since the trial results, suggests that investors are becoming increasingly wary of the company's future prospects